Compare Gilead Sciences, Inc. (GILD) vs Honeywell International Inc (HON) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Honeywell International Inc — how do they compare? Gilead Sciences, Inc. trades at $134.57 (market cap $163.51B), while Honeywell International Inc trades at $223.84 (market cap $70.60B). The key difference: Gilead Sciences, Inc. is far larger — about 2.3× Honeywell International Inc's market cap, and Honeywell International Inc pays the higher dividend (4.27%). Which is the better fit depends on your goals.
| GILD | HON | |
|---|---|---|
Market Cap | $163.51B | $70.60B |
Sector | Health | Industrials |
52-Week High | $155.80 | $248.04 |
52-Week Low | $108.22 | $188.14 |
Enterprise Value | $178.05B | $94.95B |
Dividend Yield | 2.49% | 4.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Honeywell (HON) trades at $223.30, up 0.28% with neutral technical signals. Recent financials show a P/E of 17.8 and net income margin of 10.89%, though revenue dipped to $37.44B in 2025. The company completed a 2:1 reverse stock split on June 29, 2026, and maintains strong analyst support with a $368.55 consensus price target. Earnings have consistently beaten expectations, with Q2 2026 results pending.
Outlook is cautiously optimistic given HON's automation focus post-spinoffs, but near-term execution risks and margin pressures pose challenges. The stock offers value with upside potential if management delivers on growth targets, though investors should monitor segment performance and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Honeywell International Inc
Honeywell is a global multi-industry behemoth with one of the largest installed bases of equipment. The firm operates through four business segments, including aerospace, building technologies, performance materials and technologies, and safety and productivity solutions. In recent years, the firm has made several portfolio changes, including the addition of Intelligrated in 2016, as well as the spins of Garrett Technologies and Resideo in 2018.
Read more on HON →
